GT Biopharma, Inc.
GTBP
$2.38
$0.093.93%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Total Cash And Short-Term Investments | 3.95M | 6.42M | 9.25M | 9.81M | 13.97M |
| Total Receivables | -- | -- | -- | -- | -- |
| Inventory | -- | -- | -- | -- | -- |
| Prepaid Expenses | 188.00K | 248.00K | 18.00K | 78.00K | 84.00K |
| Finance Division Loans and Leases Current | -- | -- | -- | -- | -- |
| Total Finance Division Other Current Assets | -- | -- | -- | -- | -- |
| Other Current Assets | 93.00K | 93.00K | -- | -- | -- |
| Total Current Assets | 4.23M | 6.76M | 9.27M | 9.89M | 14.06M |
|
|
|||||
| Total Current Assets | 4.23M | 6.76M | 9.27M | 9.89M | 14.06M |
| Net Property, Plant & Equipment | -- | -- | -- | 27.00K | 53.00K |
| Long-term Investments | -- | -- | -- | -- | -- |
| Goodwill | -- | -- | -- | -- | -- |
| Total Other Intangibles | -- | -- | -- | -- | -- |
| Finance Div Loans & Leases LT | -- | -- | -- | -- | -- |
| Total Finance Div Other LT Assets | -- | -- | -- | -- | -- |
| Total Other Assets | -- | -- | -- | -- | -- |
| Total Assets | 4.23M | 6.76M | 9.27M | 9.91M | 14.11M |
|
|
|||||
| Total Accounts Payable | 3.85M | 2.61M | 1.72M | 3.21M | 4.33M |
| Total Accrued Expenses | 1.80M | 1.87M | 1.77M | 963.00K | 1.20M |
| Short-term Debt | -- | -- | -- | -- | -- |
| Current Portion of Long-Term Debt/Capital Leases | -- | -- | -- | -- | -- |
| Finance Division Debt Current | -- | -- | -- | 30.00K | 58.00K |
| Total Finance Division Other Current Liabilities | 252.00K | 182.00K | 277.00K | 394.00K | 1.05M |
| Total Other Current Liabilities | 252.00K | 182.00K | 277.00K | 394.00K | 1.05M |
| Total Current Liabilities | 5.90M | 4.66M | 3.76M | 4.60M | 6.63M |
|
|
|||||
| Total Current Liabilities | 5.90M | 4.66M | 3.76M | 4.60M | 6.63M |
| Long-Term Debt | -- | -- | -- | -- | -- |
| Short-term Debt | -- | -- | -- | -- | -- |
| Capital Leases | -- | -- | -- | -- | -- |
| Finance Division Debt Non Current | -- | -- | -- | -- | -- |
| Total Finance Division Other Non Current Liabilities | -- | -- | -- | -- | -- |
| Total Other Liabilities | -- | -- | -- | -- | -- |
| Total Liabilities | 5.90M | 4.66M | 3.76M | 4.60M | 6.63M |
|
|
|||||
| Common Stock & APIC | 693.56M | 693.55M | 693.55M | 689.64M | 689.54M |
| Retained Earnings | -695.23M | -691.45M | -688.04M | -684.33M | -682.07M |
| Treasury Stock & Other | -- | -- | -- | -- | -- |
| Total Common Equity | -1.67M | 2.10M | 5.51M | 5.31M | 7.48M |
|
|
|||||
| Preferred Stock Redeemable | -- | -- | -- | -- | -- |
| Preferred Stock Non Redeemable | -- | -- | -- | -- | -- |
| Preferred Stock Convertible | 1.00K | 1.00K | 1.00K | 1.00K | 1.00K |
| Preferred Stock, Others | -- | -- | -- | -- | -- |
| Total Preferred Equity | 1.00K | 1.00K | 1.00K | 1.00K | 1.00K |
|
|
|||||
| Total Common Equity | -1.67M | 2.10M | 5.51M | 5.31M | 7.48M |
| Total Preferred Equity | 1.00K | 1.00K | 1.00K | 1.00K | 1.00K |
| Total Minority Interest | -- | -- | -- | -- | -- |
| Total Equity | -1.67M | 2.10M | 5.51M | 5.31M | 7.48M |
|
|
|||||